Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06926920 · ClinicalTrials.gov registry record · Phase 1
A Study of Sacituzumab Govitecan Given at an Alternative Dose and Schedule in Participants With Advanced Triple-Negative Breast Cancer
A Phase 1 study of Triple Negative Breast Cancer, sponsored by Gilead Sciences.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 100
- Enrollment target
- 16
- Study locations
NCT06926920: Recruiting Phase 1 study of Triple Negative Breast Cancer, sponsored by Gilead Sciences.
NCT06926920 is a Phase 1 study of Triple Negative Breast Cancer that is actively recruiting participants, run by Gilead Sciences. The registered enrollment target is 100 participants, below the 246-participant average among 118 other Triple Negative Breast Cancer trials with a reported enrollment target (59% lower). The trial reports 16 study locations across 10 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06926920, a Phase 1 study of Triple Negative Breast Cancer, is actively recruiting participants, sponsored by Gilead Sciences.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 100 participants
- Enrollment target
- 16
- Study locations
Study Summary
The goal of this clinical study is to learn more about the study drug sacituzumab govitecan-hziy (SG) given at an alternative dose and schedule, in participants with triple-negative breast cancer (TNBC). The primary objectives of this study are to assess the safety and tolerability of SG given at alternate dose and schedule, to assess the effect on objective response rate (ORR) and progression-free survival (PFS).
Conditions Studied
Interventions
- DRUG Sacituzumab Govitecan-hziy (SG)
Study Locations (16)
Other
- Seoul National University Hospital - Seoul
- Severance Hospital, Yonsei University Health System - Seoul
- Asan Medical Center - Seoul
- Samsung Medical Center - Seoul
Tennessee
- West Cancer Centre - Germantown
- SCRI Oncology Partners - Nashville
- Tennessee Oncology, PLLC - Nashville
Queensland
- Sunshine Coast University Private Hospital - Birtinya
- John Flynn Private Hospital - Tugun
California
- Los Angeles Cancer Network (LACN) - Good Sam - Los Angeles
Georgia
- Winship Cancer Institute - Emory University - Atlanta
Kansas
- The University of Kansas Hospital - Westwood
Missouri
- Siteman Cancer Center - St Louis
Texas
- Texas Oncology - DFW - Dallas
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2025-04-30 |
| Est. Completion | 2028-06 |
| Phase | Phase 1 |
What NCT06926920 shows while recruiting
NCT06926920 is an interventional study that assigns participants to a tested intervention. The registered 100 participants enrollment target is mid-sized for trials with a published cap, below the 246-participant average among 118 other Triple Negative Breast Cancer trials with a reported enrollment target (59% lower).
The record links to 1 condition, with Triple Negative Breast Cancer appearing as the primary indexed condition, and to 1 intervention - of which Sacituzumab Govitecan-hziy (SG) is the first listed.
NCT06926920 lists 16 locations in 10 states (Other, Tennessee, Queensland).
Frequently Asked Questions
What is clinical trial NCT06926920 about?
NCT06926920 is a clinical study titled "A Study of Sacituzumab Govitecan Given at an Alternative Dose and Schedule in Participants With Advanced Triple-Negative Breast Cancer". The goal of this clinical study is to learn more about the study drug sacituzumab govitecan-hziy (SG) given at an alternative dose and schedule, in participants with triple-negative breast cancer (TNBC). The primary objectives of this study are to assess the safety and tolerability of SG given at a...
What is the current status of trial NCT06926920?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 100 participants. The study started on 2025-04-30. Estimated completion is 2028-06.
What conditions does trial NCT06926920 study?
This clinical trial studies the following conditions: Triple Negative Breast Cancer.
What interventions are being tested in trial NCT06926920?
The interventions under investigation include: Sacituzumab Govitecan-hziy (SG) (DRUG).
Who is sponsoring clinical trial NCT06926920?
This trial is sponsored by Gilead Sciences, which has 504 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06926920 being conducted?
This trial has 16 study locations across California, Georgia, Kansas, Missouri, Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Triple Negative Breast Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06926920's enrollment target sits among peer trials
100 51st of 118 higher than 67 of 118 other Triple Negative Breast Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Triple Negative Breast Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Dose Escalation and Dose Expansion Study of Intratumoral ONM-501 Alone and in Combination With Cemiplimab in Patients With Advanced Solid Tumors and Lymphomas.
RECRUITING · Phase 1
-
Phase 1 Trial of ZM008 as Single Agent and in Combination With Pembrolizumab in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
-
A Beta-only IL-2 ImmunoTherapY Study
RECRUITING · Phase 1
-
Study of CRX100 as Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Solid Malignancies
RECRUITING · Phase 1
-
First-in-Human Study of ATX-295, an Oral Inhibitor of KIF18A, in Patients With Advanced or Metastatic Solid Tumors, Including Ovarian Cancer
RECRUITING · Phase 1
-
Phase I Study of [177Lu]Lu-NNS309 in Patients With Pancreatic, Lung, Breast and Colorectal Cancers
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01048281 · 100 participants
Clinical & Pathological Studies of Upper Gastrointestinal Carcinoma
- NCT01161199 · 100 participants
The Use of Leukapheresis to Support HIV Pathogenesis Studies
- NCT01327690 · 100 participants · Early Phase 1
Mental Health in Veterans and Families After Group Therapies
- NCT01730781 · 100 participants
Imaging Cannabinoid Receptors Using Positron Emission Tomography (PET) Scanning
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI